N-[4-(氨基甲基)苄基]-N,N-二乙胺 | 84227-70-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[4-(氨基甲基)苄基]-N,N-二乙胺
• 英文名称: p-(diethylaminomethyl)benzylamine
• 英文别名: p-Diethylaminomethylbenzylamine；N,N-diethyl-p-xylylenediamine；α'-Amino-α-diaethylamino-p-xylol；N,N-Diaethyl-p-xylylendiamin；(4-aminomethyl-benzyl)-diethyl-amine；4-diethylaminomethyl-benzylamine；N-[4-(aminomethyl)benzyl]-N,N-diethylamine；N-[[4-(aminomethyl)phenyl]methyl]-N-ethylethanamine
• CAS: 84227-70-3
• 化学式: C₁₂H₂₀N₂
• mdl: MFCD07343995
• 分子量: 192.304
• InChiKey: UYVJKNXIPRXTID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  N-[4-(氨基甲基)苄基]-N,N-二乙胺 在 溶剂黄146 、 sodium nitrite 作用下， 生成 (4-((diethylamino)methyl)phenyl)methanol
  参考文献：
  名称：

  Determination of Macronutrients, by Chemical Analysis, of Home-Prepared Milk Feeding Bottles and their Contribution to the Energy and Protein Requirements of Infants from High and Low Socioeconomic Classes

  摘要：

  Objectives: To determine the macronutrients composition of home-prepared milk feeding bottles, by chemical analysis, and assess their contribution to the energy and protein requirements of children under two years of age from high (HSE) and low (LSE) socioeconomic classes.Methods: 72 samples were analyzed for energy density and protein, fat and carbohydrate content: 41 from the LSE group and 31 from the HSE group. The assessment of the percentages of the energy and protein requirements met by the consumption of the milk bottles was calculated as follows: the energy and protein per 100 mL obtained through chemical analysis were multiplied by the volume consumed at each feeding, then by the number of feedings per day, the results divided by the energy and protein requirements and multiplied by 100. Energy and protein requirements were those recommended by the FAO/WHO/UNU Committee and the Food and Nutrition Board. The children's weight-for-age index was assessed.Results: Unmodified cow's milk was largely consumed by both groups. The addition of sugar and other ingredients to the milk was significantly higher in the LSE group. Moisture, protein and fat content were lower in the LSE group. whereas carbohydrate and energy content were higher. The percentages of energy and protein requirements provided by feeding bottles were higher in the LSE group. Children in the LSE group had lower z-scores for weight-for-age.Conclusions: Differences in the preparation practices led to differences in the chemical results. The feeding bottles in the LSE group were high in energy, due to the addition of sugar and cereals to the milk in the bottle. The milk feeding bottles were an important weaning food providing more than 50% and 100% of the children's energy and protein requirements, respectively. The children's weight-for-age index was within the normal Lb-aits.

  DOI：

  10.1080/07315724.2002.10719222
• 作为产物：
  描述：

  p-(diethylaminomethyl)benzonitrile 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以67%的产率得到N-[4-(氨基甲基)苄基]-N,N-二乙胺
  参考文献：
  名称：

  Synthesis of New 4-Aminoquinolines and Evaluation of Their In Vitro Activity against Chloroquine-Sensitive and Chloroquine-Resistant Plasmodium falciparum

  摘要：

  氯喹曾是抗击恶性疟原虫的首选药物，但由于抗药性广泛存在，其疗效现已受到严重限制。阿莫地喹是已知最有效的 4-氨基喹啉类抗疟药物之一，对耐氯喹的寄生虫仍然有效，但与醌-亚胺代谢物有关的毒性问题限制了它在临床上的使用。为了寻找既能保留阿莫地喹的抗疟活性，又能避免醌-亚胺代谢物毒性的新化合物，我们合成了五种 4-氨基喹啉类化合物，这些化合物的分子侧链中缺少羟基环，因此无法生成有毒的醌-亚胺。这些新化合物对氯喹敏感和抗氯喹的恶性疟原虫菌株显示出较高的体外效力（低纳摩尔 IC50），明显优于氯喹，与阿莫地喹相当，同时对 L6 大鼠成纤维细胞和 MRC5 人类肺细胞毒性较低，代谢稳定性与阿莫地喹相当或高于阿莫地喹。计算研究表明，化合物 4 通过位于联苯态的 HOMO 与血红素结合，具有独特的模式，这可能是该化合物具有较高抗疟活性的部分原因。

  DOI：

  10.1371/journal.pone.0140878

文献信息

• Adenosine receptor ligands and their use in the treatment of disease
  申请人：——

  公开号：US20010027196A1

  公开（公告）日：2001-10-04

  The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation and they may be active as muscle relaxants, antipsychotics, anti epileptics, anticonvulsants and cardiaprotective agents.

  这项发明涉及含有至少一个氮原子的环状杂芳化合物，以及它们在制造用于治疗与腺苷受体调节剂相关的疾病的药物中的应用，如阿尔茨海默病、帕金森病、神经保护、精神分裂症、焦虑、疼痛、呼吸功能障碍、抑郁症、哮喘、过敏反应、缺氧、缺血、癫痫、物质滥用、镇静，它们可能作为肌肉松弛剂、抗精神病药、抗癫痫药、抗惊厥药和心脏保护剂而具有活性。
• Cyclovinylogues of Procainamide
  作者：Piero Valenti、Maurizia Mazzotti、Angela Rampa、Maria J. Magistretti

  DOI：10.1002/ardp.19823151205

  日期：——

  Three isomeric cyclovinylogues of procainamide, in which a benzene ring is interposed between the methylene groups of the basic chain, are described. Appreciable dissociation has been achieved between local anesthetic and antiarrhythmic activities.

  描述了普鲁卡因酰胺的三种异构环乙烯基化合物，其中苯环插入在基本链的亚甲基之间。局部麻醉剂和抗心律失常活性之间已经实现了明显的分离。
• 2-Aminocarbonyl-9H-purine derivatives
  申请人：Pfizer Inc

  公开号：US20040077584A1

  公开（公告）日：2004-04-22

  The present invention relates to compounds of the formula: 1 and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.

  本发明涉及公式1的化合物：1及其药学上可接受的盐和溶剂，以及制备这些化合物的中间体、含有这些化合物的组合物的制备过程和用途。
• Pyridone compounds useful in treating Alzheimer's disease
  申请人：Hoffmann-La Roche Inc.

  公开号：US06030984A1

  公开（公告）日：2000-02-29

  The invention is concerned with the use of bi- and tricyclic pyridone compounds of the formula where A, R.sup.1, R.sup.3, R.sup.4, and R.sup.7 are described herein and of their pharmaceutically acceptable salts for the production of medicaments for the prophylaxis or treatment of illnesses which are connected with an inhibition of .beta.-amyloid peptide activity, especially for the treatment of Alzheimer's disease.

  本发明涉及使用公式中A、R.sup.1、R.sup.3、R.sup.4和R.sup.7所描述的双环和三环吡啶酮化合物及其药学上可接受的盐，用于生产用药物，以预防或治疗与β-淀粉样肽活性抑制有关的疾病，特别是用于治疗阿尔茨海默病。
• <i>N</i>-Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease
  作者：Chenxi Du、Lei Wang、Qianwen Guan、Hongyu Yang、Tingkai Chen、Yijun Liu、Qihang Li、Weiping Lyu、Xin Lu、Ying Chen、Yang Liu、Hui Liu、Feng Feng、Wenyuan Liu、Zongliang Liu、Wei Li、Yao Chen、Haopeng Sun

  DOI：10.1021/acs.jmedchem.2c00944

  日期：2022.8.25

  almost equal to the treatment with 1 mg/kg rivastigmine, against the cognitive impairment induced by Aβ1–42. The pharmacokinetics studies characterized the metabolic stability of S11-1014. Thus, N-benzyl benzamide inhibitors are promising compounds with drug-like properties for improving cognitive dysfunction, providing a potential strategy for the treatment of Alzheimer’s disease.

  在此，我们报告了一系列针对丁酰胆碱酯酶 (BChE) 的选择性亚纳摩尔抑制剂。这些带有新型N-苄基苯甲酰胺支架的化合物可抑制 BChE，IC 50从皮摩尔到纳摩尔。表面等离子共振测定证实了抑制活性，显示出亚纳摩尔K D值，这表明化合物通过直接与BChE结合发挥抑制作用。几种化合物显示出通过氧化损伤模型验证的神经保护作用。此外，体内急性毒性试验证明了S11-1014和S11-1033的安全性。在行为研究中，0.5 mg/kg S11-1014或S11-1033对 Aβ 1-42诱导的认知障碍表现出显着的治疗效果，几乎等同于 1 mg/kg 卡巴拉汀的治疗。药代动力学研究表征了S11-1014的代谢稳定性。因此，N-苄基苯甲酰胺抑制剂是一种很有前途的化合物，具有改善认知功能障碍的药物样特性，为治疗阿尔茨海默病提供了潜在的策略。